Cargando…
Building in-house PBPK modelling tools for oral drug administration from literature information
The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug development decision making process has rapidly increased in the last years. These kind of models are examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic f...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Association of Physical Chemists
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957249/ https://www.ncbi.nlm.nih.gov/pubmed/35350741 http://dx.doi.org/10.5599/admet.638 |
_version_ | 1784676727261233152 |
---|---|
author | Grandoni, Silvia Cesari, Nicola Brogin, Giandomenico Puccini, Paola Magni, Paolo |
author_facet | Grandoni, Silvia Cesari, Nicola Brogin, Giandomenico Puccini, Paola Magni, Paolo |
author_sort | Grandoni, Silvia |
collection | PubMed |
description | The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug development decision making process has rapidly increased in the last years. These kind of models are examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic framework different information as soon as they become available along the drug development. For this reason PBPK models can be used with different aims, from the early stages of drug development up to the clinical phases. Different software tools are nowadays available. They can be categorized in “designed software” and “open software”. The first ones typically include commercial platforms expressly designed to implement PBPK models, in which the model structure is pre-defined, assumptions are generally not explicitly declared and equations are hidden to the user. Even if the software is validated and routinely used in the pharmaceutical industry, sometimes they do not allow working with the flexibility needed to cope with specific applications/tasks. For this reason, some scientists prefer to define and implement their own PBPK tool in “open” software. This paper shows how to build an in-house PBPK tool from species-related physiological information available in the literature and a limited number of drug specific parameters generally made available by the drug development process. It also reports the results of an evaluation exercise that compares simulated plasma concentration-time profiles and related pharmacokinetic (PK) parameters (i.e., AUC, C(max) and T(max)) with literature and in-house data. This evaluation involved 25 drugs with different physico-chemical properties, intravenously or orally administrated in three different species (i.e., rat, dog and man). The comparison shows that model predictions have a good degree of accuracy, since the average fold error for all the considered PK parameters is close to 1 and only in few cases the fold error is greater than 2. In summary, the paper demonstrates that addressing specific aims when needed is possible by creation of in-house PBPK tools with satisfactory performances and it provides some suggestions how to do that. |
format | Online Article Text |
id | pubmed-8957249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | International Association of Physical Chemists |
record_format | MEDLINE/PubMed |
spelling | pubmed-89572492022-03-28 Building in-house PBPK modelling tools for oral drug administration from literature information Grandoni, Silvia Cesari, Nicola Brogin, Giandomenico Puccini, Paola Magni, Paolo ADMET DMPK Original Scientific Paper The interest in using physiologically-based pharmacokinetic (PBPK) models as a support to the drug development decision making process has rapidly increased in the last years. These kind of models are examples of the “bottom up” modelling strategy, which progressively integrates into a mechanistic framework different information as soon as they become available along the drug development. For this reason PBPK models can be used with different aims, from the early stages of drug development up to the clinical phases. Different software tools are nowadays available. They can be categorized in “designed software” and “open software”. The first ones typically include commercial platforms expressly designed to implement PBPK models, in which the model structure is pre-defined, assumptions are generally not explicitly declared and equations are hidden to the user. Even if the software is validated and routinely used in the pharmaceutical industry, sometimes they do not allow working with the flexibility needed to cope with specific applications/tasks. For this reason, some scientists prefer to define and implement their own PBPK tool in “open” software. This paper shows how to build an in-house PBPK tool from species-related physiological information available in the literature and a limited number of drug specific parameters generally made available by the drug development process. It also reports the results of an evaluation exercise that compares simulated plasma concentration-time profiles and related pharmacokinetic (PK) parameters (i.e., AUC, C(max) and T(max)) with literature and in-house data. This evaluation involved 25 drugs with different physico-chemical properties, intravenously or orally administrated in three different species (i.e., rat, dog and man). The comparison shows that model predictions have a good degree of accuracy, since the average fold error for all the considered PK parameters is close to 1 and only in few cases the fold error is greater than 2. In summary, the paper demonstrates that addressing specific aims when needed is possible by creation of in-house PBPK tools with satisfactory performances and it provides some suggestions how to do that. International Association of Physical Chemists 2019-02-23 /pmc/articles/PMC8957249/ /pubmed/35350741 http://dx.doi.org/10.5599/admet.638 Text en Copyright © 2018 by the authors. https://creativecommons.org/licenses/by/3.0/This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ). |
spellingShingle | Original Scientific Paper Grandoni, Silvia Cesari, Nicola Brogin, Giandomenico Puccini, Paola Magni, Paolo Building in-house PBPK modelling tools for oral drug administration from literature information |
title | Building in-house PBPK modelling tools for oral drug administration from literature information |
title_full | Building in-house PBPK modelling tools for oral drug administration from literature information |
title_fullStr | Building in-house PBPK modelling tools for oral drug administration from literature information |
title_full_unstemmed | Building in-house PBPK modelling tools for oral drug administration from literature information |
title_short | Building in-house PBPK modelling tools for oral drug administration from literature information |
title_sort | building in-house pbpk modelling tools for oral drug administration from literature information |
topic | Original Scientific Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957249/ https://www.ncbi.nlm.nih.gov/pubmed/35350741 http://dx.doi.org/10.5599/admet.638 |
work_keys_str_mv | AT grandonisilvia buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation AT cesarinicola buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation AT brogingiandomenico buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation AT puccinipaola buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation AT magnipaolo buildinginhousepbpkmodellingtoolsfororaldrugadministrationfromliteratureinformation |